{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:41:48Z","timestamp":1793788908358,"version":"4.6.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009259","name":"The University of Texas Medical Branch at Galveston Institute for Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001439"],"award-info":[{"award-number":["UL1 TR001439"]}],"id":[{"id":"10.13039\/100009259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007913","name":"Institute for Translational Neuroscience","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007865","name":"University of Texas Medical Branch","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.amjmed.2024.10.039","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T10:23:32Z","timestamp":1731234212000},"page":"441-448.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6006-3903","authenticated-orcid":false,"given":"Dietrich von Kuenssberg","family":"Jehle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheed","family":"Sunesra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9829-1250","authenticated-orcid":false,"given":"Krishna K.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro A.","family":"Joglar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obadiah D.","family":"Michler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diann","family":"Gaalema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Hayek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Jneid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.amjmed.2024.10.039_bib0001","first-page":"1","article-title":"Deaths: leading causes for 2019","volume":"70","author":"Heron","year":"2021","journal-title":"Natl Vital Stat Rep"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.039_bib0002","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/nau.23320","article-title":"Relationship between lower urinary tract symptoms and cardiovascular risk scores including Framingham risk score and ACC\/AHA risk score","volume":"37","author":"Lee","year":"2018","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"10.1016\/j.amjmed.2024.10.039_bib0003","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.aju.2013.03.003","article-title":"Erectile dysfunction and cardiovascular disease","volume":"11","author":"Jackson","year":"2013","journal-title":"Arab J Urol"},{"issue":"25 suppl 2","key":"10.1016\/j.amjmed.2024.10.039_bib0004","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.amjmed.2024.10.039_bib0005","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2012.09.006","article-title":"The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia","volume":"63","author":"Giuliano","year":"2013","journal-title":"Eur Urol"},{"issue":"13","key":"10.1016\/j.amjmed.2024.10.039_bib0006","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/bph.14205","article-title":"PDE5 inhibitors\u2014pharmacology and clinical applications 20 years after sildenafil discovery","volume":"175","author":"Andersson","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"16","key":"10.1016\/j.amjmed.2024.10.039_bib0007","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/heartjnl-2016-310746","article-title":"Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction","volume":"103","author":"Andersson","year":"2017","journal-title":"Heart"},{"issue":"21","key":"10.1016\/j.amjmed.2024.10.039_bib0008","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/heartjnl-2015-309223","article-title":"Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality","volume":"102","author":"Anderson","year":"2016","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.039_bib0009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/jsxmed\/qdac005","volume":"20","author":"Kloner","year":"2023","journal-title":"J Sex Med"},{"issue":"7","key":"10.1016\/j.amjmed.2024.10.039_bib0010","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00345-022-04005-3","article-title":"Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms?","volume":"40","author":"Goberdhan","year":"2022","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.amjmed.2024.10.039_bib0011","doi-asserted-by":"crossref","first-page":"e12412","DOI":"10.1002\/trc2.12412","article-title":"PDE5 inhibitor drugs for use in dementia","volume":"9","author":"Hainsworth","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.039_bib0012","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13195-022-01034-3","article-title":"Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions","volume":"14","author":"Kang","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.amjmed.2024.10.039_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00067","article-title":"Using a federated network of real-world data to optimize clinical trials operations","volume":"2","author":"Topaloglu","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.amjmed.2024.10.039_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.annemergmed.2023.03.022","article-title":"Tenecteplase versus alteplase for acute stroke: mortality and bleeding complications","author":"Murphy","year":"2023","journal-title":"Ann Emerg Med"},{"issue":"6","key":"10.1016\/j.amjmed.2024.10.039_bib0015","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2147\/TCRM.S3336","article-title":"Tadalafil in the treatment of erectile dysfunction","volume":"4","author":"Coward","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"10.1016\/j.amjmed.2024.10.039_bib0016","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/jch.14435","article-title":"Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications","volume":"24","author":"Kloner","year":"2022","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"11","key":"10.1016\/j.amjmed.2024.10.039_bib0017","first-page":"81","article-title":"Sildenafil for erectile dysfunction","volume":"36","year":"1998","journal-title":"Drug Ther Bull"},{"issue":"3","key":"10.1016\/j.amjmed.2024.10.039_bib0018","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cardfail.2007.11.006","article-title":"Effects of 5\u2032-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial","volume":"14","author":"Behling","year":"2008","journal-title":"J Card Fail"},{"issue":"4","key":"10.1016\/j.amjmed.2024.10.039_bib0019","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/hc2901.093117","article-title":"Sildenafil inhibits hypoxia-induced pulmonary hypertension","volume":"104","author":"Zhao","year":"2001","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.amjmed.2024.10.039_bib0020","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/thx.2005.041954","article-title":"Phosphodiesterase type 5 and high altitude pulmonary hypertension","volume":"60","author":"Aldashev","year":"2005","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.amjmed.2024.10.039_bib0021","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10157-021-02051-6","article-title":"Reno-protective effects of phosphodiesterase 5 inhibitors","volume":"25","author":"Coskuner","year":"2021","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"10.1016\/j.amjmed.2024.10.039_bib0022","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4103\/1673-5374.200804","article-title":"PDE5 inhibitors promote recovery of peripheral neuropathy in diabetic mice","volume":"12","author":"Wang","year":"2017","journal-title":"Neural Regen Res"},{"issue":"4","key":"10.1016\/j.amjmed.2024.10.039_bib0023","doi-asserted-by":"crossref","first-page":"776","DOI":"10.5534\/wjmh.200155","article-title":"Effect of phosphodiesterase-5 inhibitors on the treatment of male infertility: a systematic review and meta-analysis","volume":"39","author":"Dong","year":"2021","journal-title":"World J Mens Health"},{"key":"10.1016\/j.amjmed.2024.10.039_bib0024","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neuropharm.2012.06.052","article-title":"Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD","volume":"64","author":"Garc\u00eda-Barroso","year":"2013","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.amjmed.2024.10.039_bib0025","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.eururo.2012.07.025","article-title":"Sildenafil effect on the human bladder involves the L-cysteine\/hydrogen sulfide pathway: a novel mechanism of action of phosphodiesterase type 5 inhibitors","volume":"62","author":"Fusco","year":"2012","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.amjmed.2024.10.039_bib0026","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/alz.12305","article-title":"Plasma hydrogen sulfide: a biomarker of Alzheimer's disease and related dementias","volume":"17","author":"Disbrow","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.amjmed.2024.10.039_bib0027","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209131","article-title":"Phosphodiesterase type 5 inhibitors in men with erectile dysfunction and the risk of Alzheimer disease: a cohort study","volume":"102","author":"Adesuyan","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.amjmed.2024.10.039_bib0028","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jhealeco.2018.10.003","article-title":"The effect of prescription drug coverage on mortality: evidence from Medicaid implementation","volume":"63","author":"Clayton","year":"2019","journal-title":"J Health Econ"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.039_bib0029","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clpt.2004.09.006","article-title":"Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo","volume":"77","author":"Ring","year":"2005","journal-title":"Clin Pharmacol Ther"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324007058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324007058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T12:49:47Z","timestamp":1753361387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934324007058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0002934324007058"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.10.039","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.10.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}